Humacyte (NASDAQ:HUMA) Cut to Sell at Wall Street Zen

Humacyte (NASDAQ:HUMA - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday.

A number of other equities research analysts also recently issued reports on the stock. HC Wainwright initiated coverage on shares of Humacyte in a research note on Wednesday, May 14th. They set a "buy" rating and a $4.00 price target on the stock. Benchmark decreased their price target on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price target on shares of Humacyte in a research note on Monday, June 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $11.71.

Humacyte Price Performance

Shares of Humacyte stock traded down $0.08 on Friday, hitting $2.33. 1,562,910 shares of the company traded hands, compared to its average volume of 3,850,366. The stock has a market capitalization of $361.43 million, a P/E ratio of -3.38 and a beta of 2.00. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.28 and a current ratio of 3.68. Humacyte has a 52 week low of $1.15 and a 52 week high of $9.79. The business has a 50-day simple moving average of $1.95 and a 200 day simple moving average of $3.12.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million. Research analysts expect that Humacyte will post -1.27 earnings per share for the current fiscal year.

Insider Buying and Selling at Humacyte

In related news, CFO Dale A. Sander purchased 20,000 shares of the business's stock in a transaction dated Thursday, April 10th. The shares were purchased at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the acquisition, the chief financial officer now owns 40,600 shares in the company, valued at approximately $62,118. This trade represents a 97.09% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Kathleen Sebelius purchased 50,000 shares of the business's stock in a transaction dated Tuesday, April 8th. The stock was bought at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the acquisition, the director now owns 91,207 shares of the company's stock, valued at approximately $120,393.24. The trade was a 121.34% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 83,993 shares of company stock worth $118,224 over the last quarter. Insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HUMA. Vontobel Holding Ltd. bought a new position in shares of Humacyte in the fourth quarter worth about $50,000. Rhumbline Advisers lifted its stake in Humacyte by 4.6% in the fourth quarter. Rhumbline Advisers now owns 114,455 shares of the company's stock worth $578,000 after acquiring an additional 5,005 shares during the period. Atria Wealth Solutions Inc. purchased a new stake in Humacyte in the fourth quarter worth about $130,000. Private Advisor Group LLC lifted its stake in Humacyte by 60.7% in the fourth quarter. Private Advisor Group LLC now owns 599,700 shares of the company's stock worth $3,028,000 after acquiring an additional 226,590 shares during the period. Finally, Rowlandmiller & PARTNERS.ADV purchased a new stake in Humacyte in the fourth quarter worth about $159,000. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.